EUVIMEDEUVIMED entdecken
Crossref

Association of pulmonary fibrosis with Methotrexate in Rheumatoid Arthritis patients

Soma Hassan, Niaz Albarznji

Journal of Sulaimani Medical College · 21.06.2026 · 16 (1)

DOI: 10.17656/jsmc.10502 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Sulaimani Medical College, online erschienen am 21.06.2026. Verfasst von Soma Hassan und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rheumatoid Arthritis (RA) is a chronic autoimmune inflammatory disease that affects joints and can lead to extra-articular manifestations, including pulmonary fibrosis (PF). Methotrexate (MTX), commonly used in RA treatment, has been associated with lung complications, though its role in the development of PF remains unclear.

Objective

The current study investigates the association between methotrexate use and pulmonary fibrosis in RA patients, focusing on clinical, sociodemographic, and treatment-related factors. Patients and Methods: A cross-sectional study was conducted from October 2024 to March 2025 at the outpatient rheumatology clinic of Rizgary General Teaching Hospital, Erbil, Iraq. A total of 86 RA patients were enrolled, with inclusion criteria of RA diagnosis for at least one year and MTX or other DMARD use. Pulmonary assessments with HRCT scans.

Results

The prevalence of pulmonary fibrosis was 14.0% (12 out of 86 patients). RA-PF patients were significantly older (63.67 ± 9.98 years) compared to RA-non-PF patients (55.89 ± 12.65 years, P = 0.046). The gender distribution was also significantly different, with fewer females in the RA-PF group (66.7% vs. 93.2%, P = 0.019). Disease duration greater than 5 years was seen in 75% of RA-PF patients, compared to 43.2% in RA-non-PF (P = 0.041). MTX (10-20 mg) was used by 91.7% of RA-PF patients compared to 62.2% of RA-non-PF patients (P = 0.045). The mean duration of MTX use was similar between groups (2.38 ± 2.68 years in RA-PF vs. 2.21 ± 2.88 years in RA-non-PF, P = 0.673). Inflammatory markers showed significantly higher levels

Zitieren

APA

Hassan, S., & Albarznji, N. (2026). Association of pulmonary fibrosis with Methotrexate in Rheumatoid Arthritis patients. Journal of Sulaimani Medical College, 16(1). https://doi.org/10.17656/jsmc.10502

Vancouver

Hassan S, Albarznji N. Association of pulmonary fibrosis with Methotrexate in Rheumatoid Arthritis patients. Journal of Sulaimani Medical College. 2026;16(1). doi:10.17656/jsmc.10502

BibTeX
@article{Hassan2026,
  author = {Hassan, Soma and Albarznji, Niaz},
  title = {Association of pulmonary fibrosis with Methotrexate in Rheumatoid Arthritis patients},
  journal = {Journal of Sulaimani Medical College},
  year = {2026},
  volume = {16},
  number = {1},
  doi = {10.17656/jsmc.10502}
}
Kostenlos starten →